GPCR Receptor

G-protein coupled receptors (GPCRs) constitute the largest membrane receptor family in humans, with over 800 identified members. They share a universal architecture: a single protein forms seven alpha-helix transmembrane helices (hence the alternative name 7TM receptors), with an extracellular domain capturing the ligand and an intracellular domain recruiting and activating heterotrimeric G proteins. This superfamily is the most important pharmacological target: over 30% of worldwide approved drugs act on a GPCR, and virtually all major therapeutic peptides (GLP-1, GIP, glucagon, oxytocin, melanocortins, ghrelin) are GPCR agonists.

The transduction mechanism follows a precise cascade. The ligand binds its extracellular site, causing a conformational rearrangement transmitted to transmembrane helices and ultimately to the intracellular domain. The heterotrimeric G protein (alpha, beta, gamma subunits) passively docked on the receptor then exchanges its GDP for GTP, then dissociates into an active Galpha subunit and a Gbeta-gamma complex. These two fragments modulate downstream effectors: adenylate cyclase to produce cAMP (Gs pathway), potassium channels, phospholipase C to generate DAG/IP3 (Gq pathway), etc. The cellular signal is amplified and integrated into a physiological response: insulin secretion for GLP-1, uterine contraction for oxytocin, appetite regulation for ghrelin.

GPCRs are classified into five classes (A, B, C, F, Others) based on architecture. Class A (rhodopsin-type) is the largest and contains biogenic amine receptors (dopamine, serotonin, adrenaline) and small peptides. Class B contains medium-sized peptide and hormone receptors — this is the class of GLP-1R, GIPR, GCGR, GHRHR, CRHR, PTHR receptors, all possessing a large N-terminal extracellular domain forming a deep binding pocket to accommodate 30-40 residue peptides. Class C groups metabotropic glutamate, GABAB, and CaSR receptors. Class F contains Wnt pathway Frizzled receptors. This architectural diversity explains each subfamily's specificity.

Beyond the simple agonist/antagonist model, GPCRs prove extraordinarily sophisticated. They signal not only via G proteins but also via beta-arrestins, which can direct parallel signaling (MAP kinases, AKT) without G protein. The biased agonist concept exploits this duality: a ligand can stabilize a preferential conformation that activates G proteins more than beta-arrestins, or vice versa. This approach is tested to dissociate beneficial effects (G-biased agonism) from side effects (arrestin-biased) in developing new opioid, GLP-1, and melanocortin agonists.

X-ray crystallography and cryo-electron microscopy have revolutionized GPCR structural understanding since 2000, resolving over 300 structures including about thirty in complex with their G protein. These structures guide rational design of new peptides and small molecules. GPCR understanding is thus an unavoidable pillar of modern pharmacology, and their importance will continue to grow with the arrival of therapies targeting orphan receptors (>100 GPCRs still lack known endogenous ligand).